Treatment decisions in metastatic colorectal cancer - beyond first and second line combination therapies by A, Vogel, RD, Hofheinz, S, Kubicka, D, Arnold

Get full text

2565 QoLiTime: Quality-of-Life (QoL) analysis of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel in daily clinical practice by Hofheinz, R.D, Al-Batran, S.E, Windemuth-Kieselbach, C, Hammerer, P

Get full text

Impaired continence function five years after intensified chemoradiation in patients with locally advanced rectal cancer by Horisberger, K, Rothenhoefer, S, Kripp, M, Hofheinz, R.D, Post, S, Kienle, P

Get full text

OC-0250: First results of the PETACC-6 randomized phase III trial in locally advanced rectal cancer by Haustermans, K, Schmoll, H.J, Price, T, Nordlinger, B, Hofheinz, R.D, Daisne, J.F, Janssens, J, Schmidt, P, Reinel, H, Van Cutsem, E

Get full text

2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy by Van Cutsem, E, Ciardiello, F, Seitz, J.F, Hofheinz, R.D, Verma, U, Garcia-Carbonero, R, Grothey, A, Miriyala, A, Kalmus, J, Shapiro, J, Falcone, A, Zaniboni, A

Get full text

36LBA Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/... by Pauligk, C, Tannapfel, A, Meiler, J, Luley, K.B, Kopp, H.G, Homann, N, Hofheinz, R.D, Schmalenberg, H, Probst, S, Haag, G.M, Egger, M, Behringer, D.M, Stoehlmacher, J, Prasnikar, N, Block, A, Trojan, J, Folprecht, G, Pohl, M, Schirmacher, P, Al-Batran, S.E

Get full text

PCN188 Did Decision-Making Models from National Guidelines Change 1st Line Treatment Strategy for Patients with Metastatic Colorectal Cancer (MCRC)? The Results of Large Population... by Kellermann, L, Hofheinz, R.D, Arnold, D

Get full text

PG 6.2 Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free surviv... by Schmoll, H-J, Haustermans, K, Price, T, Nordlinger, B, Hofheinz, R.D, Daisne, J-F, Janssens, J, Brenner, B, Schmidt, P, Reinel, H, Hollerbach, S, Caca, K, Fauth, F, Hannig, C.V, Zalcberg, J, Tebbutt, N, Mauer, M.E, Messina, C, Lutz, M, Van Cutsem, E

Get full text

Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer—a study in AIO oncologists by Büttelmann, M., Hofheinz, R.D., Kröcher, A., Ubbelohde, U., Stintzing, S., Reinacher-Schick, A., Bornhäuser, M., Folprecht, G.

Get full text

OC-0501 Chemo-RT plus induction or consolidation chemotherapy for rectal cancer: a randomised phase 2 trial by Fokas, E., Allgäuer, M., Polat, B., Klautke, G., Grabenbauer, G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.L., Schmiegel, W., Jacobasch, L., Weitz, J., Folprecht, G., Schleska-Lange, A., Grützmann, R., Schwarzbach, M., Paolucci, V., Bechstein, W.O., Friede, T., Ghadimi, M., Hofheinz, R.D., Rödel, C.

Get full text

6052 Capecitabine single agent or in combination in the routine first-line treatment of a predominantly elderly population with metastatic colorectal cancer (MCRC) by Schröder, J, Göhler, T, Grothe, W, Tschechne, B, Valdix, A.R, Harich, H.D, Klünsch, F, Hofheinz, R.D

Get full text